Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Cisplatin
Related studies linked through entity extraction aliases.
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Status
- COMPLETED
- Phase
- PHASE3
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
- Status
- WITHDRAWN
- Phase
- PHASE3
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC
- Status
- COMPLETED
- Phase
- PHASE3
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
- Status
- UNKNOWN
- Phase
- NA
Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
- Status
- UNKNOWN
- Phase
- N/A
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
- Status
- TERMINATED
- Phase
- PHASE3
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
- Status
- TERMINATED
- Phase
- PHASE3
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
- Status
- COMPLETED
- Phase
- PHASE3